Bioequivalency Study of Clarithromycin Tablets Under Fasting Conditions
NCT ID: NCT00601315
Last Updated: 2018-01-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
40 participants
INTERVENTIONAL
2003-04-30
2003-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Bioequivalency Study of Clarithromycin Tablets Under Fed Conditions
NCT00602498
Bioequivalence Study of Clarithromycin 250mg Tablets Under Fasting Conditions
NCT00774189
Comparative Bioavailability Study of Clarithromycin 250 mg Tablets
NCT00648830
Bioequivalence Study of Clarithromycin 250 mg/5 mL Powder for Oral Suspension Under Fasting Conditions
NCT00775255
Comparative Bioavailability Study of Clarithromycin 500 mg Tablets in Fed State
NCT00648128
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Clarithromycin
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Treatment with known enzyme altering drugs.
* History of allergic or adverse response to clarithromycin or any other macrolide antibiotic.
18 Years
45 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Roxane Laboratories
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Roxane Laboratories, Inc.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Mark J Allison, MD
Role: PRINCIPAL_INVESTIGATOR
MDS Pharma Services
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
MDS Pharma Services
Phoenix, Arizona, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
461-07
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.